 |
|
 |
 |
|
THURSDAY,
SEPTEMBER 20,
2007
Advances in Immunotherapy for Malignant Melanoma
A
complimentary
dinner meeting
Las
Vegas, Nevada
Chair:
Wolfram Samlowski,
M.D.
Huntsman Cancer
Institute
Salt Lake City,
Utah
Click
here to register
for this program
|
 |
|
F A C
U L T
Y |
 |
|
|
Esteban Celis, MD
H. Lee Moffitt Cancer Center
Tampa, Florida
|
Wolfram Samlowski, MD
Huntsman Cancer Institute
Salt Lake City, UT
|
|
|
|
|
S C I
E N T
I F I
C
A G E
N D A
|
|
|
6:30 pm
Registration
and reception
7:00 pm
Introduction
to the biology of melanoma
Wolfram Samlowski, MD
7:15
pm
Immunotherapy:
Harnessing the immune response to cancer
Esteban
Celis, MD
7:45 pm
Overcoming
immunologic tolerance to melanoma: Targeting CTLA-4
TBD
8:15 pm
Enhancing
the immune response to melanoma: Vaccines and other novel
biologics to stimulate and target the immune response
Wolfram
Samlowski, MD
8:45 pm
Question
and answer session
9:00 pm
Adjourn |
|
|
|
C O N
T I N
U I N
G M
E D I
C A L
E D U
C A T
I O N |
|
|
|
Imedex
Accreditation
Services,
LLC
is
accredited
by
the
Accreditation
Council
for
Continuing
Medical
Education
to
provide
continuing
medical
education
for
physicians.
Imedex
Accreditation
Services,
LLC
designates
this
educational
activity
for
a
maximum
2.0
of
AMA
PRA
Category
1
Credit(s)TM.
Physicians
should
only
claim
credit
commensurate
with
the
extent
of
their
participation
in
the
activity.
|
|
|
|
W H O
S H O
U L D
A T T
E N D
? |
|
|
|
This
educational
activity
is
specifically
designed
for
medical
oncologists,
dermatologists,
and
other
physicians,
physicians-in-training,
and
healthcare
professionals
interested
in
and/or
involved
in
the
care
of
patients
with
melanoma
and
its
consequences.
No
specialized
knowledge
or
skill
other
than
general
familiarity
with
internal
medicine,
oncology,
or
dermatology
is
required
for
successful
participation
in
this
activity.
|
|
|
|
O B J
E C T
I V E
S |
|
|
|
After
successfully
completing
this
educational
activity,
participants
should
be
able
to:
- Describe
the
basic concepts
of immunotherapy
and how
each type
can be
used as
a treatment modality in
oncology
-
Discuss
the
role
immune
tolerance
plays
in
allowing
the
growth
and
spread
of
cancer
cells
-
Explain
the
specific
role
of
CTLA-4
in
maintaining
immune
tolerance
and
how
inhibiting
its
function
can
be
used
in
the
treatment
of
malignant
melanoma
-
Compare
and
contrast
emerging
biological
agents,
primarily
vaccines
and
cytokines,
that
are
used
to
stimulate
and
target
a
patient’s
own
immune
response
against
a
tumor
and
are
currently
in
trials
for
use
against
melanoma
|
|
|
|
|
R E G
I S T
R A T
I O N |
|
|
|
Click
here
to
register
for
this
program
You may register online by September
19,
2007
or by
calling
Imedex
at
+1
(678)
242
0906.
Registration
confirmations
will
be
issued
before
the meeting. This is a complimentary dinner meeting
and
space
is limited. To confirm your attendance, please register by September 19, 2007.
|
|
|
|
G
E N E
R A L
I N F
O R M
A T I
O N |
|
|
|
Meeting
Location
Sensi
(inside Bellagio)
3600 Las Vegas Blvd. South
Las Vegas, Nevada
Tel.: 702-693-8800
|
|
|
|
O R G
A N I
Z E R |
|
|
|
|
|
©
2007 Imedex Accreditation
Services, LLC.
All rights reserved.
Reproduction in
whole or part
is prohibited
without prior
written consent
from Imedex and
contributing faculty.
|
